Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Trenibrorher@w:o - Novartis&Sirona?!

<< Previous

Bullboard Posts

Next >>

Comment by 24minus7on Jun 25, 2023 7:19am

109 Views

Post# 35513421

RE:RE:Trenibrorher@w:o - Novartis&Sirona?!

Licogliflozin is an SGLT1/2 inhibitor developed for patients with NASH (non-alcoholic steatohepatitis) and liver fibrosis.

I think TFC-039 might be more likely to be included in LNP023 Iptacopan(APPLAUSE-IgAN). Promising results from phase 3 trials are expected in H2 2023.

https://www.novartis.com/news/media-releases/novartis-phase-...

Iptacopan could be a practice-changing oral medicine.

If this is really the case, then I can very well imagine that Novartis wants to and will secure the licensing rights as soon as possible.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario